Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering IL-10 has "very good" efficacy, toxicity data in early clinicals, exec tells Alex. Brown.

Executive Summary

SCHERING-PLOUGH IL-10 EFFICACY, TOXICITY DATA appear to bode well for the biosynthetic interleukin-10 product, Senior VP-Investor Relations and Corporate Communications Geraldine Foster suggested May 14 at the Alex. Brown health care seminar in Baltimore. IL-10 has had "some very good early stage trials in terms of efficacy and lack of toxicity," she said. The product is in clinicals for Crohn's disease and ulcerative colitis. IL-10 also is in early clinicals for rheumatoid arthritis.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028189

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel